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Background: Percutaneous Mitral Valvuloplasty (PMV) has emerged as an effective nonsurgical technique for the treatment of patients with 
symptomatic MS during pregnancy.
Methods: From November 1999 to Dec. 2008, 117 pregnant women (among 5700 PMV patients - 2.1%) were performed PMV using Inoue balloon 
at Vietnam Heart Institute. The transthoracic echocardiography was used in combination with intermittent fluoroscopy to limit the radiation exposure 
time. A detailed clinical, echocardiographic, hemodynamic assessment was analyzed pre, post procedure, at every 3 months for the first year and at 
6-month interval thereafter. The pregnancy and newborn outcomes were also followed.
Results: MS pregnant women were 27.6 years old on average (ranged 22-42) and the mean length of pregnancy was 24.2 ± 5.6 weeks. Echo score 
of mitral valve was 7.1 ± 2.3. The procedure was technically successful in all cases but 1 (0.85%), who developed cardiac tamponade after septal 
punture. This patient was saved with cardiocentesis and procedure was re - performed successfully after one week. No procedure related death was 
reported. The good result (MVA post PMV greater than 1.5cm2) was obtained in 95 cases (81.19 %). The total mean duration of the procedure was 
35.25 ± 14.28 min and that of fluoroscopy 2.55 ± 1.28 min (from 1 min 59 sec to 3 min 15 sec). The fluoroscopy time was significantly shorter 
than that of usual patients not using echo guided (2 min 23 sec vs. 7 min 23 sec, p< 0.01). The mitral valve area increased from 0.7 ± 0.3 to 1.8 
± 0.4 cm2 (on echocardiography). A reduction in mean transmitral valve gradient (MVG) was from 22 ± 6 to 8 ± 2 mmHg. There were no maternal 
or fetal deaths. All patients delivered at full term but 19 (without major complications), 47 vaginally and 70 by caesarean section. After average 36 
months follow-up (range, 3 to 60) all children had normal growth.
Conclusions: During pregnancy, Percutaneous Mitral Valvuloplasty could be considered as the treatment of choice for severe mitral stenosis which 
are refractory to medical treatment. Using echocardiography guided can reduce the fluoroscopy time.
